TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02288923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sub arachnoid analgesia
Description: Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
Study: NCT00551213

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Robatumumab
Study: NCT00551213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study: NCT01786265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given via injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given via injection
Study: NCT00551213

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX/XELOX
Description: Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
Study: NCT01786265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given via injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilutamide
Description: Given PO
Study: NCT00551213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
Study: NCT01144117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoietin 48000 IU given I.V. in 17 courses
Study: NCT02288923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation or general anaesthesia
Description: After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation or general anaesthesia
Description: After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-medication
Description: All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-medication
Description: All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
Study: NCT02107274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Azithromycin
Description: In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
Study: NCT02578602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetate Disodium
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI with gadoxetate disodium
Study: NCT02293707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX301
Description: GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX301
Description: GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX301
Description: GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG.
Study: NCT01786265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT03584152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: Opioid Analgesics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol 325Mg Caplet
Description: Non opioid analgesics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg
Description: Non opioid analgesics
Study: NCT01946854

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year.
Study: NCT02781519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Active THC (0.015mg/kg) administered over 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
Study: NCT06094738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant under fasted conditions
Description: Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
Study: NCT02789878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Androgen Deprivation Therapy
Study: NCT02288923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative medication
Description: If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative medication
Description: If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative analgesia - morphine
Description: Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight \>70kg 2 hourly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative analgesia - morphine
Description: Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight \>70kg 2 hourly.
Study: NCT01084161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 5 mg IV once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 7.5 mg IV once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 15 mg IV once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 30 mg IV once per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV placebo once per day
Study: NCT02288923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative analgesia - ibuprofen and paracetamol
Description: All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative analgesia - ibuprofen and paracetamol
Description: All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular anti emetics
Description: All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
Study: NCT01084161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 10-15 mg IV once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 60 mg IV once per day
Study: NCT01260974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: 50mg/dd for 21dd, starting within 24h from Liver Transplantation.
Study: NCT03940469

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Injection
Description: 8 mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: 100 microgram dexmedetomidine
Study: NCT02477943

Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.

Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
Study: NCT02288923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular anti emetics
Description: All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
Study: NCT01067794

Intervention type: DRUG
Intervention: Any platinum-based doublet chemotherapy
Description: Dosage, dosage form, frequency and duration according to daily hospital practice

Intervention type: DRUG
Intervention: Any platinum-based doublet chemotherapy
Description: Dosage, dosage form, frequency and duration according to daily hospital practice

Intervention type: DRUG
Intervention: Any platinum-based doublet chemotherapy
Description: Dosage, dosage form, frequency and duration according to daily hospital practice

Intervention type: DRUG
Intervention: Any platinum-based doublet chemotherapy
Description: Dosage, dosage form, frequency and duration according to daily hospital practice

Intervention type: DRUG
Intervention: Any platinum-based doublet chemotherapy
Description: Dosage, dosage form, frequency and duration according to daily hospital practice
Study: NCT05694117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-determine sequence exercise program
Description: The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
Study: NCT06094738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant after a high-fat meal
Description: Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant after a low-fat meal
Description: Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
Study: NCT04555239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model (FDM)
Description: Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~* Herniated trigger points are single areas of sharp pain within soft tissue.~* Continuum distortions are single points of sharp pain overlying bony tissues.~* Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model (FDM)
Description: Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~* Herniated trigger points are single areas of sharp pain within soft tissue.~* Continuum distortions are single points of sharp pain overlying bony tissues.~* Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands.
Study: NCT02789878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Corticosteroid
Study: NCT02789878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: CYP17 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: CYP17 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Androgen-receptor antagonist
Study: NCT04559334

Intervention type: DEVICE
Group type: OTHER
Intervention: Tetrasodium EDTA Catheter Lock Solution
Description: KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
Study: NCT04000880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health
Description: AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health
Description: AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health
Description: AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet-Exercise
Description: Diet-Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-Diet
Description: Exercise-Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Diet and Exercise
Description: Combined Diet and Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Diet and Exercise
Description: Combined Diet and Exercise